Construction and Validation of a Predictive Model for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors Receiving Taxane-Based Chemotherapy: A Multicenter Cross-sectional Study.

IF 2.4 3区 医学 Q1 NURSING
Ruo-Lin Li, Jing Li, Jun-E Liu, Li-Xiao Bai, Juan Liu, Ci Li
{"title":"Construction and Validation of a Predictive Model for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors Receiving Taxane-Based Chemotherapy: A Multicenter Cross-sectional Study.","authors":"Ruo-Lin Li, Jing Li, Jun-E Liu, Li-Xiao Bai, Juan Liu, Ci Li","doi":"10.1097/NCC.0000000000001516","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer survivors (BCSs) undergoing taxane-based chemotherapy frequently experience chemotherapy-induced peripheral neuropathy (CIPN), potentially affecting their quality of life. Early identification of high-risk survivors can help mitigate the severity of CIPN.</p><p><strong>Objective: </strong>To construct and validate a predictive model for CIPN in BCSs receiving taxane-based chemotherapy.</p><p><strong>Methods: </strong>In this multicenter cross-sectional study conducted across 10 hospitals in China between April 2022 and March 2023, 569 BCSs were randomly assigned to development (n = 401) or validation (n = 168) sets (ratio, 7:3). Predictive factors were identified by multiple logistic regression, and a nomogram was constructed. Model discrimination was evaluated using receiver operating characteristic curves and area under the curve values, whereas calibration was assessed with the Hosmer-Lemeshow test and calibration curves. Decision curve analysis was performed to evaluate clinical utility.</p><p><strong>Results: </strong>CIPN was observed in 82.8% of the survivors. The nomogram included 5 factors: treatment with paclitaxel liposome, treatment with albumin-bound paclitaxel, number of chemotherapy cycles, vitamin D deficiency, and fatigue levels. The area under the curve values for the development and validation sets were 0.866 (95% confidence interval, 0.817-0.914) and 0.848 (95% confidence interval, 0.761-0.935), respectively, indicating good performance. The Hosmer-Lemeshow test and decision curve analysis confirmed good calibration and clinical utility.</p><p><strong>Conclusions: </strong>The nomogram model demonstrates good discrimination and calibration, offering a practical and visual tool for identifying high-risk survivors for CIPN.</p><p><strong>Implications for practice: </strong>This predictive model can assist clinicians in the early identification of BCSs at high risk for CIPN and in promptly implementing preventive measures.</p>","PeriodicalId":50713,"journal":{"name":"Cancer Nursing","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/NCC.0000000000001516","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Breast cancer survivors (BCSs) undergoing taxane-based chemotherapy frequently experience chemotherapy-induced peripheral neuropathy (CIPN), potentially affecting their quality of life. Early identification of high-risk survivors can help mitigate the severity of CIPN.

Objective: To construct and validate a predictive model for CIPN in BCSs receiving taxane-based chemotherapy.

Methods: In this multicenter cross-sectional study conducted across 10 hospitals in China between April 2022 and March 2023, 569 BCSs were randomly assigned to development (n = 401) or validation (n = 168) sets (ratio, 7:3). Predictive factors were identified by multiple logistic regression, and a nomogram was constructed. Model discrimination was evaluated using receiver operating characteristic curves and area under the curve values, whereas calibration was assessed with the Hosmer-Lemeshow test and calibration curves. Decision curve analysis was performed to evaluate clinical utility.

Results: CIPN was observed in 82.8% of the survivors. The nomogram included 5 factors: treatment with paclitaxel liposome, treatment with albumin-bound paclitaxel, number of chemotherapy cycles, vitamin D deficiency, and fatigue levels. The area under the curve values for the development and validation sets were 0.866 (95% confidence interval, 0.817-0.914) and 0.848 (95% confidence interval, 0.761-0.935), respectively, indicating good performance. The Hosmer-Lemeshow test and decision curve analysis confirmed good calibration and clinical utility.

Conclusions: The nomogram model demonstrates good discrimination and calibration, offering a practical and visual tool for identifying high-risk survivors for CIPN.

Implications for practice: This predictive model can assist clinicians in the early identification of BCSs at high risk for CIPN and in promptly implementing preventive measures.

基于紫杉烷化疗的乳腺癌幸存者化疗诱导周围神经病变预测模型的构建和验证:一项多中心横断研究。
背景:接受紫杉烷化疗的乳腺癌幸存者(BCSs)经常会经历化疗诱导的周围神经病变(CIPN),这可能会影响他们的生活质量。早期识别高风险幸存者有助于减轻CIPN的严重程度。目的:建立并验证接受紫杉烷类化疗的bcs患者CIPN的预测模型。方法:在2022年4月至2023年3月在中国10家医院进行的这项多中心横断面研究中,569个bcs被随机分配到开发组(n = 401)或验证组(n = 168)(比例为7:3)。采用多元逻辑回归方法对预测因素进行识别,并构建方差图。模型判别采用受试者工作特征曲线和曲线下面积评价,校正采用Hosmer-Lemeshow检验和校正曲线评价。采用决策曲线分析评价临床应用价值。结果:82.8%的幸存者出现CIPN。nomogram包括5个因素:紫杉醇脂质体治疗、白蛋白结合紫杉醇治疗、化疗周期数、维生素D缺乏和疲劳程度。开发集和验证集曲线下面积分别为0.866(95%置信区间0.817-0.914)和0.848(95%置信区间0.761-0.935),性能良好。Hosmer-Lemeshow检验和决策曲线分析证实了良好的校准和临床应用。结论:nomogram模型具有良好的鉴别和校准能力,为识别CIPN高危幸存者提供了一种实用且直观的工具。实践意义:该预测模型可以帮助临床医生早期识别有CIPN高风险的bcs,并及时实施预防措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Nursing
Cancer Nursing 医学-护理
CiteScore
4.80
自引率
3.80%
发文量
244
审稿时长
6-12 weeks
期刊介绍: Each bimonthly issue of Cancer Nursing™ addresses the whole spectrum of problems arising in the care and support of cancer patients--prevention and early detection, geriatric and pediatric cancer nursing, medical and surgical oncology, ambulatory care, nutritional support, psychosocial aspects of cancer, patient responses to all treatment modalities, and specific nursing interventions. The journal offers unparalleled coverage of cancer care delivery practices worldwide, as well as groundbreaking research findings and their practical applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信